title: Novel therapies in the treatment of systemic lupus erythematosus.
abstract: This review highlights the advances made in the use of biological and immunomodulatory agents in systemic lupus erythematosus. Although there have been disappointments (eg, anti-CD40 ligand, DNAse), it is clear that DHEA and mycophenolate mofetil will have a place in the management of the disease. In our opinion, leflunomide and LJP-394 are the most promising therapies currently, under study.
authors.affiliation: Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. dequetc@cshs.org
authors.forename: C R
authors.initials: CR
authors.lastname: Dequet
authors.forename: D J
authors.initials: DJ
authors.lastname: Wallace
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans; D007105:Immune Complex Diseases / Q000517:prevention & control; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001688:Biological Products